Immune cell contribution to drug-resistance in Multiple Myeloma

Basic Information

Funding Cycle : 2022-2023
Name : Lucia Chen
Type of Award : Career Development Award
Home Institution : Weatherall Institute of Molecular Medicine, United Kingdom
Host Institution : Mount Sinai Hospital, New York, NY USA


Utilizing longitudinal bone marrow samples from relapsed-refractory MM patients treated with Elotuzumab-Iberdomide-Dexamethasone (EId), the study aims to evaluate immunologic profiles and specific biomarkers such as IKZF1 in immune cells. The project has three specific aims: 1) to profile the immune system of MM patients before EId treatment to identify correlations with high-risk MM phenotypes, 2) to compare pre- and post-treatment immune profiles to assess reversibility and predictive value for progression-free and overall survival, and 3) to examine the expression of IKZF1 and IKZF3 in CD138+ bone marrow immune cells and their impact on T-cell activation and prognosis with EId treatment. This research seeks to enhance understanding of immunologic mechanisms underlying MM drug resistance and potential strategies for improving patient outcomes.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events